MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs

MACROGENICS INC

Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.
Gilead gets exclusive option to license MGD024 (Phase 1 CD123×CD3 DART) for AML and MDS.
MacroGenics to continue Phase 1 study; Gilead may exercise option at predefined decision points.
Tiered double-digit royalties on MGD024 net sales; flat royalties on products from two research programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.